ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of “Moderate Buy” from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $12.50.

A number of research firms recently commented on ALXO. UBS Group decreased their price objective on shares of ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 16th. Lifesci Capital cut ALX Oncology from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 31st. Stifel Nicolaus reissued a “hold” rating and set a $3.00 price target (down from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a research note on Tuesday, August 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research note on Monday, August 12th.

ALX Oncology Stock Up 0.6 %

Shares of ALX Oncology stock opened at $1.56 on Wednesday. ALX Oncology has a 12-month low of $1.42 and a 12-month high of $17.83. The firm has a market capitalization of $81.28 million, a PE ratio of -0.42 and a beta of 1.00. The company has a quick ratio of 4.39, a current ratio of 4.39 and a debt-to-equity ratio of 0.06. The stock’s fifty day moving average is $2.13 and its 200-day moving average is $7.46.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.01. Equities analysts anticipate that ALX Oncology will post -3.04 earnings per share for the current year.

Institutional Investors Weigh In On ALX Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. CANADA LIFE ASSURANCE Co acquired a new position in ALX Oncology in the first quarter worth approximately $27,000. EntryPoint Capital LLC acquired a new position in shares of ALX Oncology during the 1st quarter worth $32,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of ALX Oncology by 394.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after purchasing an additional 5,200 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after purchasing an additional 6,888 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new stake in ALX Oncology in the second quarter worth $63,000. 97.97% of the stock is owned by hedge funds and other institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.